Francis Price, MD
Ophthalmology · Indianapolis, INNPI 1568464287
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,461 of the $67,372 with a category attached, or 70.4%. 35 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 32.4% of the total. Reporting peaked in 2020 at $30,762 and has fallen 87.3% since, to $3,893 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $452.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$22K
- Kala Pharmaceuticals, Inc.$13K
- Haag-streit USA, Inc.$12K
- Alcon$6K
- Bausch & Lomb Americas Inc.$5K
- Aerie Pharmaceuticals, Inc.$2K
- plus $8K from 29 others
Across 173 payments — averaging $2602.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$264K
- Alcon Research LLC$112K
- Aerie Pharmaceuticals, Inc.$68K
- Bausch & Lomb Americas Inc.$5K
- Eyepoint US, Inc.$920
What the payments were for
- Consulting fees$47,46170%
- Speaking & faculty fees$1,9013%
- Travel & lodging$5161%
- Food & beverage$6,87010%
- Education$210%
- Gifts$10,60416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 4 | $21,825 |
| Kala Pharmaceuticals, Inc. | 3 | $13,214 |
| Haag-streit USA, Inc. | 12 | $11,993 |
| Alcon | 26 | $5,891 |
| Bausch & Lomb Americas Inc. | 16 | $4,886 |
| Aerie Pharmaceuticals, Inc. | 4 | $2,024 |
| GSK | 1 | $1,750 |
| Lensar, Inc. | 9 | $1,641 |
| Oculus, Inc. | 2 | $1,102 |
| W. L. Gore & Associates, Inc. | 1 | $650 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $396 |
| AbbVie(2 entities) | 15 | $371 |
| Rxsight Inc | 3 | $285 |
| Eyepoint US, Inc. | 4 | $272 |
| Harrow Eye, LLC | 3 | $207 |
| Mallinckrodt Hospital Products Inc. | 3 | $174 |
| Oyster Point Pharma, Inc. | 3 | $90 |
| Novartis | 5 | $83 |
| Carl Zeiss Meditec USA, Inc. | 2 | $69 |
| Sun Pharmaceutical Industries Inc. | 3 | $52 |
| Biotissue Holdings Inc. | 3 | $49 |
| Ocular Therapeutix, Inc. | 1 | $46 |
| Rayner Intraocular Lenses Limited | 2 | $43 |
| Johnson & Johnson Vision Care, Inc. | 1 | $38 |
| LKC Technologies, Inc. | 1 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Medline Industries LP | 1 | $21 |
| Dompe US, Inc. | 1 | $20 |
| Omeros Corporation | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
| Ivantis, Inc | 1 | $14 |
| Sight Sciences, Inc. | 1 | $13 |
| Thea Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$13,200
- Octopus 600 Pro$10,604
- WaveLight EX500 Excimer Laser$4,025
- MIEBO$2,575
- XIIDRA$2,200
- LENSAR LASER SYSTEM$1,413
- Pentacam OCT$1,000
- VYZULTA$875
- Wavelight$855
- Product in Development$650
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- VEVYE$136
- ACTHAR$127
- DEXYCU$116
- CIRRUS HD-OCT$105
- Clarus 700$105
- NA$102
- Tecnis IOL$102
How this compares
$67,372 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $39,816 |
| Prednisolone Acetate | 644 | $31,624 |
| Fluorometholone | 352 | $30,742 |
| VevyeCyclosporine | 29 | $22,036 |
| XiidraLifitegrast | 12 | $19,055 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 51 | $13,847 |
| LumiganBimatoprost | 23 | $13,773 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $9,911 |
| Cyclosporine | 36 | $7,329 |
| RhopressaNetarsudil Mesylate | 15 | $6,796 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $6,650 |
| ValacyclovirValacyclovir Hcl | 78 | $5,752 |
| TobradexTobramycin/Dexamethasone | 18 | $4,780 |
| Ofloxacin | 402 | $4,574 |
| Tobradex StTobramycin/Dexamethasone | 18 | $4,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $371 | $60,23986 claims |
| Harrow Eye, LLCVevye | $207 | $22,03629 claims |
| Bausch & Lomb Americas Inc.Xiidra | $4,886 | $19,05512 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $2,024 | $16,70744 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $32 | $4,19318 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $16 | $3,49022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.